Posted by Michael Wonder on 13 May 2022
Women with moderate to severe fibroids set to be offered new one a day treatment following final draft guidance from NICE
13 May 2022 - Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (Ryeqo, Gedeon Ritcher) in final draft guidance.
Relugolix with estradiol and norethisterone acetate for treating uterine fibroids will be available three months after the final guidance is published.
